Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the American Association for Cancer Research (AACR) Annual Meeting 2022

About this update from Rain Enhancement Technologies Holdco, Inc.

NEWARK, Calif. , April 01, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a poster presentation and two trials in progress at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from April 8-13, 2022 . Poster Presentation Title: Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors Abstract Number: 1174 / 4 Presenter: Vijaya G. Tirunagaru , Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics , Newark, CA Poster Session Date and Time: Monday, April 11, 2022 , 9:00 a.m. – 12:30 p.m. CT Location: Poster Section 27 Trial in Progress Title: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53 -wild type and MDM2 -amplified advanced or metastatic solid tumors (MANTRA-2) Abstract Number: CT123/5 Presenter: Ecaterina I. Dumbrava , M.D., Medical Oncologist, The University of Texas MD Anderson Cancer Center Session Date and Time Monday, April 11, 2022 , 9:00 a.m. – 12:30 p.m. CT Location: Poster Section 34 Trial in Progress Title: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas Abstract Number: CT235/6 Presenter: Mrinal M. Gounder , M.D., Medical Oncologist, Memorial Sloan Kettering Cancer Center Session Date and Time: Tuesday, April 12, 2022 , 1:30 p.m. – 5:00 p.m. CT Location: Poster Section 36 A copy of the presentation materials can be accessed by visiting the " Resources ” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website. About Rain Therapeutics Inc. Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. Media Contact Jordyn Temperato LifeSci Communications [email protected] Investor Contact Bob Yedid LifeSci Advisors +1.646.597.6989 [email protected] Source: Rain Therapeutics

View stock analysis, news, and events for Rain Enhancement Technologies Holdco, Inc.